News | Women's Health | April 08, 2021

Mobidiag to be Acquired by Hologic for $795M

Transaction will accelerate global growth of Mobidiag’s differentiated molecular platform, which offers ease of use, multiplex capability and rapid turnaround time 

Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.

April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.

Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing, allowing clinicians to identify which organism is responsible for an infection quickly, accurately and efficiently.

“We are very excited to join Hologic’s diagnostic business,” said Tuomas Tenkanen, Mobidiag’s Chief Executive Officer. “Under the Hologic umbrella our business will continue to be committed to its existing customer base in Europe, including our home markets of Finland, France, Sweden and UK, however, Hologic’s commercial expertise, scale and investment strength, will accelerate the broader market adoption of our products. In addition, Hologic’s established U.S. regulatory and market development capabilities will rapidly facilitate the introduction of our products and maximize their potential in the United States.”

“Acquiring Mobidiag will further strengthen our international diagnostics businesses by providing a European R&D and manufacturing center of excellence, enabling us to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of use, multiplex capability and rapid turnaround time,” said Jan Verstreken, Group President, International at Hologic.  “We believe that Mobidiag has a highly complementary product offering and has developed a differentiated platform that addresses many of the historical challenges of multiplexed point-of-care molecular testing.”

“One of our key goals is to use our strong cash flow to create a larger, faster growing company for a post-pandemic world,” said Steve MacMillan, Hologic’s chairman, president and chief executive officer.  “Mobidiag provides an exceptional new growth platform, which will generate long-term value by enabling us to enter the acute care market, which is expected to roughly double in the next five years, with a differentiated, highly competitive solution.”

Mobidiag generated approximately $42 million  of revenue in calendar 2020.  Hologic intends to invest in assay development to drive growth of the Novodiag platform. Hologic expects to finance the transaction with cash on hand and borrowing on its existing line of credit.

The acquisition is expected to close early in the fourth quarter of fiscal 2021, subject to receipt of certain required regulatory approvals and other customary closing conditions, including FDI approval in Finland and France.

J.P. Morgan AG acted as sole financial advisor and Roschier Attorneys acted as legal advisor to Mobidiag.

For more information: www.mobidiag.com

Related Content

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
Elsevier’s STATdx, a leading radiology diagnostic decision support solution, now includes select Merit-Based Incentive Payment System (MIPS) Measures validated by MDinteractive
News | Clinical Decision Support | April 02, 2021
April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership w
While the COVID-19 crisis is challenging, the pandemic is also giving researchers an opportunity to discover new approaches to saving lives. A study published in the JAMA Network Open on Thursday, March 25, 2021, recommends a new way for triaging mammogram patients during times of limited capacity, such as pandemic surges, when individuals may also experience anxiety about COVID-19.

Getty Images

News | Breast Imaging | April 01, 2021
April 1, 2021 — While the COVID-19 crisis is challenging, the pandemic is also giving researchers an opportunity to d
In looking at the broader impact of the COVID-19 pandemic on health and wellbeing, public health experts are examining screening rates for cancer. A new study looking at U.S. mammography screening rates during the first five months of the pandemic found both a strong rebound in breast cancer screening rates and a concerning cumulative deficit in mammograms due to missed appointments, as well as uncovering disparities when looking at screening according to race

Getty Images

News | Breast Imaging | April 01, 2021
April 1, 2021 — In looking at the broader impact of the...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc
Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Lung Imaging | March 29, 2021
March 29, 2021 — According to ARRS' 
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of